These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7118282)

  • 41. [Treatment of iron overload due to repeated transfusions with subcutaneous infusions of desferrioxamine (author's transl)].
    Girot R; Thévenin M; Bouveret JP; Jeannel F; Rymer JC
    Arch Fr Pediatr; 1980 Apr; 37(4):241-7. PubMed ID: 7406638
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapy and monitoring of hypersiderosis in chronic renal insufficiency.
    Hilfenhaus M; Koch KM; Bechstein PB; Schmidt H; Fassbinder W; Baldamus CA
    Contrib Nephrol; 1984; 38():167-74. PubMed ID: 6713893
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The treatment of hemosiderosis in thalassaemia major with desferrioxamine-B.
    Kirimlidis S; Philippidis P; Drossos C; Economidis J
    Helv Paediatr Acta; 1966 Sep; 21(4):343-50. PubMed ID: 5997620
    [No Abstract]   [Full Text] [Related]  

  • 44. Iron chelating therapy in thalassemia: current problems.
    Russo G
    Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385
    [No Abstract]   [Full Text] [Related]  

  • 45. [Possibilities and limitation of desferrioxamine treatment of transfusion hypersiderosis in children].
    Orsini A; Passeron P; Perrimond H; Pierron H
    Pediatrie; 1968; 23(5):588-9. PubMed ID: 5675452
    [No Abstract]   [Full Text] [Related]  

  • 46. Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis.
    Seifert A; von Herrath D; Schaefer K
    Q J Med; 1987 Dec; 65(248):1015-24. PubMed ID: 3455553
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Iron overload? In sickle cell disease?
    Day S; Dancy R; Kelly K; Wang W
    MCN Am J Matern Child Nurs; 1993; 18(6):330-5. PubMed ID: 8295522
    [No Abstract]   [Full Text] [Related]  

  • 48. [Use of desferrioxamine B in normal subjects and in patients with increased iron storage].
    Muranda M; Velasco M; Giménez E; Ruiz J; Bastías E; Rodriguez J; Etcheverry R; Guzmán C; Regonesi C; Janklevich S
    Rev Med Chil; 1965 Apr; 93(4):127-33. PubMed ID: 5832943
    [No Abstract]   [Full Text] [Related]  

  • 49. Continuous high-dose intravenous desferrioxamine treatment for iron overload.
    Sidi Y; Shaklai M; Liban E; Pinkhas J
    Isr J Med Sci; 1981 May; 17(5):348-51. PubMed ID: 7263191
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Diagnosis and therapy of iron overload with desferrioxamine].
    Andres J; Stobbe H
    Z Gesamte Inn Med; 1984 Apr; 39(8):167-9. PubMed ID: 6730593
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.
    Vichinsky E; Pakbaz Z; Onyekwere O; Porter J; Swerdlow P; Coates T; Lane P; Files B; Mueller BU; Coïc L; Forni GL; Fischer R; Marks P; Rofail D; Abetz L; Baladi JF
    Acta Haematol; 2008; 119(3):133-41. PubMed ID: 18408362
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Long-term study in congenital refractory anemia and secondary siderosis].
    Tuschy U; Schmidt U; Meinhold J; Wutke K
    Z Gesamte Inn Med; 1982 Apr; 37(7):213-7. PubMed ID: 7102009
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Desferrioxamine in patients with hemochromatosis and hemosiderosis].
    Maspes V; Tamigaki M; Gomes ZJ; Jamra M
    Rev Hosp Clin Fac Med Sao Paulo; 1966; 21(4):181-95. PubMed ID: 5918167
    [No Abstract]   [Full Text] [Related]  

  • 54. Recent developments in iron chelation therapy.
    Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E
    Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Deferoxamine-enhanced fecal losses of aluminum and iron in a patient undergoing continuous ambulatory peritoneal dialysis.
    McCarthy JT; Kurtz SB; Mussman GV
    Am J Med; 1987 Feb; 82(2):367-70. PubMed ID: 3812538
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Evaluation of iron balance in homozygous beta-thalassemia subjects treated with desferrioxamine administered subcutaneously].
    Ferrara M; Galdo Capotorti M; Ponte G; Esposito L
    Pediatria (Napoli); 1983; 91(4):371-7. PubMed ID: 6545400
    [No Abstract]   [Full Text] [Related]  

  • 57. [A new iron chelating agent: desferrioxamine B (Desferal). Clinico-pharmacological observations. Cases].
    Gallinelli R; Coppini D
    Minerva Med; 1965 Nov; 56(92):3980-5. PubMed ID: 5845686
    [No Abstract]   [Full Text] [Related]  

  • 58. [Continuous subcutaneous desferrioxamine infusions in patients with hemosiderosis (author's transl)].
    Tillmann W; König R; Schröder K; Schröter W
    Monatsschr Kinderheilkd; 1982 Mar; 130(3):171-2. PubMed ID: 7087975
    [No Abstract]   [Full Text] [Related]  

  • 59. [Subcutaneous administration of deferoxamine in a patient with panmyelopathy and post-transfusion hemosiderosis].
    Zdziarska B; Urasiński I
    Pol Arch Med Wewn; 1987 Jul; 78(1):48-51. PubMed ID: 3271285
    [No Abstract]   [Full Text] [Related]  

  • 60. [Further experiences with iron-chelating therapy (desferrioxamine and ascorbic acid) in siderochromatosis and Cooley's disease].
    Cartei G; Cazzavillan M; Chisesi T; Battista R; Barbui T; Dini E
    Minerva Med; 1978 Mar; 69(13):811-21. PubMed ID: 643223
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.